Hepatorenal Syndrome Treatment Market Trends

Statistics for the 2023 & 2024 Hepatorenal Syndrome Treatment market trends, created by Mordor Intelligence™ Industry Reports. Hepatorenal Syndrome Treatment trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Market Trends of Hepatorenal Syndrome Treatment Industry

This section covers the major market trends shaping the Hepatorenal Syndrome Treatment Market according to our research experts:

Therapuetics Segment is the Fastest Growing Segment of the Hepatorenal Syndrome Treatment Market.

The therapeutics segment is expected to grow at a greater phase as the patients prefer taking drugs than undergoing surgeries. Furthermore, increasing fast track and orphan designations to the drugs is further boosting the segment. Several drugs have received orphan drug designation, thereby accelerating their approval process, and this can act as a factor pushing the growth of the therapeutics segment. For instance, in November 2018, BioVie Inc. announced that the FDA granted Orphan Drug designation to its Terlipressin drug for the treatment of the hepatorenal syndrome. The designation for orphan drugs allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials, along with seven years of market exclusivity upon regulatory approval. This is likely to drive the hepatorenal syndrome treatment market during the forecast period.

fast track

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors, such as the presence of key players, established healthcare infrastructure, increased prevalence of severe liver damage and cirrhosis are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to the US Department of Health and Human Services,1 in 400 adults in the United States has cirrhosis for the year 2018. As per the statistics the increasing patient pool and increasing disposable revenue in this country boost the market growth of the region.

Hepatorenal

Hepatorenal Syndrome Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)